Benefits of Stereotaxis Robotic Technology in COVID-19 Patient Highlighted in Publication
July 13 2020 - 9:05AM
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, today
announced a publication in the European Heart Journal highlighting
the benefits of Stereotaxis’ robotic technology in a COVID-19
patient.
The publication concludes that catheter ablation
“should be performed preferably with a remote navigation system in
order to minimize the infectious risk of the staff of the
electrophysiology laboratory.”
Dr. Giovanni Forleo and colleagues at Luigi
Sacco Hospital at the University of Milan presented the case of a
68-year-old patient diagnosed with COVID-19 who was admitted to the
emergency department with multiple episodes of sustained
ventricular tachycardia and electrical storm. COVID-19 has been
associated with cardiovascular manifestations including
life-threatening ventricular arrhythmias. The patient’s arrhythmia
was treated using catheter cardiac ablation with Stereotaxis’
robotic magnetic navigation system.
The publication states, “We used a remote
magnetic navigation system since it has been thought to be superior
to manual navigation for VT ablation (due to better contact force
and stability) and in order to minimize unnecessary exposure of the
electrophysiology laboratory staff to a likely COVID-19
patient.”
The procedure was successful and the patient did
not experience ventricular tachycardia recurrence. The patient also
recovered from COVID-19.
“We are proud to advance robotics in
interventional medicine for the benefit of patients and healthcare
professionals,” said David Fischel, Stereotaxis Chairman and CEO.
“We are particularly grateful of the pronounced benefit of our
technology for the most complex procedures in critical patients,
while preserving the safety of the medical staff.”
The publication can be found at
https://academic.oup.com/ehjcr/article/doi/10.1093/ehjcr/ytaa217/5867241.
To access the complete database of more than 400 scientific
publications referencing Stereotaxis technology, visit
www.RoboticEP.com/clinical-data/publications-database/.
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute “forward-looking” statements, usually containing the
words “believe,” “estimate,” “project,” “expect” or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to continue to manage expenses
and cash burn rate at sustainable levels, continued acceptance of
the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare policy in the United
States, including changes in government reimbursement of
procedures, dependence upon third-party vendors, timing of
regulatory approvals, the impact of the recent coronavirus
(COVID-19) pandemic and our response to it, and other risks
discussed in the Company's periodic and other filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside
of the Company's control. In addition, these orders and commitments
may be revised, modified, delayed or canceled, either by their
express terms, as a result of negotiations, or by overall project
changes or delays.
Company Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Sep 2023 to Sep 2024